Vivid Dx Secures $15M Seed Round and New CEO to Advance Rapid Sepsis Diagnostics

New updates have been reported about Vivid Dx.

Vivid Dx has raised $15 million in seed financing and appointed Keith O’Neill as chief executive officer, marking a pivotal step in its effort to commercialize rapid blood-based diagnostics for severe infections and antimicrobial resistance. The round was co-led by Oxford Science Enterprises and Cedars-Sinai Intellectual Property Co., with participation from Jameel Investment Management Company and other strategic backers, positioning the company with capital and partnerships to move from technical proof to clinical validation.

The Oxford-based company is building a direct-from-blood platform that applies advanced sample preparation, Raman spectroscopy, proprietary spectral databases, and AI-driven analysis to identify pathogens and support phenotypic antimicrobial susceptibility testing within hours rather than days. Vivid Dx has already demonstrated proof-of-concept, including high-purity bacterial recovery, AI-enhanced Raman signal interpretation, and a spectral library of thousands of clinical isolates, with preclinical data showing about 99% accuracy in pathogen identification and roughly 92% concordance with gold-standard AST methods.

This capability targets a critical gap in sepsis care, where clinicians currently must initiate broad-spectrum empiric therapy while waiting for culture results, contributing to unnecessary antibiotic use and rising antimicrobial resistance, projected to be linked to tens of millions of deaths globally in the coming decades. By enabling earlier, targeted treatment decisions that integrate into hospital workflows and stewardship programs, Vivid Dx aims to help reduce ICU stays, lower treatment costs, and improve clinical outcomes while protecting last-line therapies.

O’Neill brings 25 years of experience across genomics, diagnostics innovation, and company building, including roles at MIT’s Human Genome Project, Abbott, and as CEO of Novus Diagnostics, where he advanced rapid tests for bloodstream infections. He has stated that his immediate focus is leading Vivid Dx through clinical studies using patient-derived samples and generating the evidence required for routine adoption in hospitals worldwide.

Investors at Oxford Science Enterprises and Cedars-Sinai emphasize that the company’s challenge is not just speed but delivering reliable, workflow-compatible results that hospitals can trust at scale, underscoring the importance of upcoming validation milestones for Vivid Dx’s commercial outlook. As regulatory, stewardship, and cost pressures intensify, successful clinical performance could position Vivid Dx as a strategically important player in infectious disease diagnostics, with upside for health systems seeking to manage drug-resistant infections more effectively.